Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study

被引:12
作者
Chen, Zhen-Ping [1 ]
Li, Pei-Jing [1 ]
Li, Gang [1 ]
Tang, Ling [1 ]
Zhen, Ying-Zi [1 ]
Wu, Xin-Yi [1 ]
Cheng, Xiao-Ling [1 ]
Luke, Koon Hung [2 ,3 ,4 ]
Blanchette, Victor S. [5 ]
Poon, Man-Chiu [6 ,7 ,8 ]
Ding, Qiu-Lan [9 ]
Wu, Run-Hui [1 ]
机构
[1] Capital Med Univ, Natl Key Discipline Pediat, Beijing Key Lab Pediat Hematol Oncol, Hematol Oncol Ctr,Beijing Childrens Hosp,Minist E, Beijing 100045, Peoples R China
[2] Childrens Hosp Eastern Ontario, Dept Pediat & Lab Med, Ottawa, ON K1H 8L1, Canada
[3] Childrens Hosp Eastern Ontario, Hemophilia Clin, Ottawa, ON K1H 8L1, Canada
[4] Univ Ottawa, Ottawa, ON K1H 8L1, Canada
[5] Univ Toronto, Res Inst, Hosp Sick Children, Dept Pediat & Child Hlth Evaluat Sci,Div Hematol, Toronto, ON M5G 1X8, Canada
[6] Univ Calgary, Foothills Hosp, Dept Med Pediat & Oncol, Calgary, AB T2N 2T9, Canada
[7] Univ Calgary, Foothills Hosp, Southern Alberta Rare Blood & Bleeding Disorders, Calgary, AB T2N 2T9, Canada
[8] Calgary Hlth Reg, Calgary, AB T2N 2T9, Canada
[9] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Lab Med, Sch Med, Shanghai 200025, Peoples R China
关键词
Boys; Factor VIII; Hemophilia A; Pharmacokinetics; DOSE SECONDARY PROPHYLAXIS; RECOMBINANT FACTOR-VIII; HALF-LIFE; FVIII; CHILDREN; RECOVERY; EFFICACY; PLASMA;
D O I
10.4103/0366-6999.233604
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although much attention has been paid to the pharmacokinetics (PKs) of different factor VIII (FVIII) concentrates in persons with hemophilia A (HA), limited information is available in young boys with severe HA. In this study, we aimed to assess the PK parameters of FVIII products in boys with severe HA in China. Methods: A total of 36 boys (plasma-derived [pd]-FVIII, n = 15; recombinant [r] FVIII, n = 21) were enrolled between January 2015 and May 2016 in Beijing Children's Hospital. PK characteristics of FVIII products were studied according to a reduced 4-sampling time point design (1 h, 9 h, 24 h, and 48 h postinfusion). Results: The mean FVIII half-life (t(1/2)) was 10.99 +/- 3.45 h (range 5.52-20.02 h), the mean in vivo recovery (IVR) was 2.01 +/- 0.42 IU/dl per rU/kg (range 1.24-3.02 IU/l per IU/kg) and mean clearance (CL) of FVIII is 4.34 +/- 1.58 ml'kg(-1) h(-1) (range 2.29-7.90 ml.kg(-1) h(-1)). We also analyzed the influence of several parameters that potentially modulate FVIII PK. The age was closely associated with FVIII half-life (R-2 = 0.32, P < 0.01). The t(1/2) of FVIII increased by 0.59 h per year. Besides age, von Willebrand factor antigen (VWF: Ag) also was associated with FVIII half-life (R-2 = 0.52, P < 0.01). Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 +/- 0.68 h vs. 12.3 +/- 0.79 h, t = 2.70, P = 0.01). The FVIII IR correlated with age (R-2 = 0.21, P < 0.01) and VWF: Ag level (R-2 = 0.28, P < 0.01). CL rates were faster in young patients and in those with low-VWF: Ag levels. CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 +/- 0.38 vs. 4.00 +/- 0.32 ml.kg(-1) h(-1), t = 2.53, P = 0.02). Conclusions: Chinese boys with severe HA have similar PK values to other ethnic groups and large differences in FVIII PK between individual patients. Age, blood group, and VWF: Ag levels are important determining factors for FVIII CL.
引用
收藏
页码:1781 / U28
页数:6
相关论文
共 50 条
  • [31] Factor VIII half-life and clinical phenotype of severe hemophilia A
    van Dijk, Karin
    van der Bom, Johanna G.
    Lenting, Peter J.
    de Groot, Philip G.
    Mauser-Bunschoten, Eveline P.
    Roosendaal, Goris
    Grobbee, Diederick E.
    van den Berg, H. Marijke
    HAEMATOLOGICA, 2005, 90 (04) : 494 - 498
  • [32] Observational study of recombinant factor VIII-Fc, rFVIIIFc, in hemophilia A
    Ebbert, Patrick T.
    Xavier, Frederico
    Malec, Lynn M.
    Seaman, Craig D.
    Ragni, Margaret, V
    THROMBOSIS RESEARCH, 2020, 195 : 51 - 54
  • [33] Factor VIII haplotypes in severe hemophilia A patients in India
    Patricia Pinto
    Kanjaksha Ghosh
    Shrimati Shetty
    Annals of Hematology, 2013, 92 : 999 - 1000
  • [34] Hemodialysis in a patient with severe hemophilia A and factor VIII inhibitor
    Gopalakrishnan, Natarajan
    Usha, Thiruvengadam
    Thopalan, Balasubramaniyan
    Dhanapriya, Jeyachandran
    Dineshkumar, Thanigachalam
    Thirumalvalavan, Kaliaperumal
    Sakthirajan, Ramanathan
    HEMODIALYSIS INTERNATIONAL, 2016, 20 (04) : E11 - E13
  • [35] Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
    Collins, P. W.
    Blanchette, V. S.
    Fischer, K.
    Bjorkman, S.
    Oh, M.
    Fritsch, S.
    Schroth, P.
    Spotts, G.
    Astermark, J.
    Ewenstein, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (03) : 413 - 420
  • [36] Reduced-intensity, risk factor–stratified immunosuppression for acquired hemophilia A: single-center observational study
    Christiane Dobbelstein
    Georgios Leandros Moschovakis
    Andreas Tiede
    Annals of Hematology, 2020, 99 : 2105 - 2112
  • [37] Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis
    Miners, A. H.
    Krishnan, S.
    Pasi, K. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (11) : 2141 - 2147
  • [38] Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens
    Collins, P. W.
    Bjorkman, S.
    Fischer, K.
    Blanchette, V.
    Oh, M.
    Schroth, P.
    Fritsch, S.
    Casey, K.
    Spotts, G.
    Ewenstein, B. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (02) : 269 - 275
  • [39] Joint status and related risk factors in patients with severe hemophilia A: a single-center cross-sectional study
    Zhao, Liang
    Yang, Hongbin
    Li, Yaochun
    Wang, Zhongqing
    Zhou, Li
    Zhao, Xielan
    Peng, Jie
    HEMATOLOGY, 2022, 27 (01) : 80 - 87
  • [40] Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A
    Cannavo, Antonino
    Valsecchi, Carla
    Garagiola, Isabella
    Palla, Roberta
    Mannucci, Pier Mannuccio
    Rosendaal, Frits R.
    Peyvandi, Flora
    BLOOD, 2017, 129 (10) : 1245 - 1250